Advisory Services Network’s Heron Therapeutics HRTX Stock Holding History

Advisory Services Network’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53K	Sell	1,918 -16,956	-90%	-$19.6K	﹤0.01%	4204
2025 Q4	$24.5K	Buy	18,874 +18,114	+2,383%	+$22.4K	﹤0.01%	1789
2025 Q3	$958	Buy	+760	New	+$1.21K	﹤0.01%	3939
2024 Q1	–	Sell	-1,479	Closed	-$2.51K	–	2431
2023 Q4	$2.51K	Buy	+1,479	New	+$1.63K	﹤0.01%	3336
2023 Q2	–	Sell	-760	Closed	-$1.15K	–	2418
2023 Q1	$1.15K	Sell	760 -200	-21%	-$501	﹤0.01%	3588
2022 Q4	$2.4K	Buy	+960	New	+$3.09K	﹤0.01%	3379

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Advisory Services Network's HRTX Position: Q1 2026 in Review

Advisory Services Network reduced its Heron Therapeutics (HRTX) stake by 90% in Q1 2026, selling an estimated $19.6K and leaving 1,918 shares worth $1.53K. The position accounts for ﹤0.01% of the portfolio, ranked #4204.

Advisory Services Network first reported a position in HRTX in Q4 2022 and has held it in 6 quarters since. The position peaked at $24.5K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

Advisory Services Network held 1,918 shares of Heron Therapeutics worth $1.53K as of Q1 2026.
Advisory Services Network sold 16,956 Heron Therapeutics shares in Q1 2026, an estimated $19.6K.
Heron Therapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #4204 holding.
Advisory Services Network first reported a position in Heron Therapeutics in Q4 2022 and has held it in 6 quarters since.
Advisory Services Network's Heron Therapeutics position peaked at $24.5K in Q4 2025.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.